12 Severe Hypertriglyceridemia (sHTG): An Underrecognized, Life-Threatening Condition 11:15 a.m.-12 p.m. Heart Theater 2 SPONSOR: Ionis Pharmaceuticals The Impact of Cardiac Myosin Inhibition on Cardiac Structure and Function 11:15 a.m.-12 p.m. Heart Theater 1 SPONSOR: Bristol Myers Squibb Transforming Heart Failure Treatment: Advances and Opportunities in Gene Therapy 11:15 a.m.-12 p.m. Learning Studio 1 SPONSOR: AskBio Inc. Navigating the Complexities: Considerations in Heart Failure Management in Patients With ATTR-CM 11:30 a.m.-12:45 p.m. Industry RM 245 SPONSOR: Pfizer, Inc. Improving Cardiovascular Outcomes in Patients at High CV Risk 12:30-1:15 p.m. Learning Studio 2 SPONSOR: Amgen Inc. A Strategic Approach to Treating Hyperkalemia in HFrEF 12:30-1:15 p.m. Heart Theater 1 SPONSOR: AstraZeneca Spotlight on a Treatment Option for Pulmonary Arterial Hypertension (PAH) 12:30-1:15 p.m. Learning Studio 1 SPONSOR: Merck & Co., Inc. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist 12:30-1:15 p.m. Learning Studio 3 SPONSOR: Eli Lilly & Company 2025 INDUSTRY EVENTS Sunday, Nov. 9
RkJQdWJsaXNoZXIy MjI2NjI=